» Articles » PMID: 15972696

Response of Memory CD8+ T Cells to Severe Acute Respiratory Syndrome (SARS) Coronavirus in Recovered SARS Patients and Healthy Individuals

Overview
Journal J Immunol
Date 2005 Jun 24
PMID 15972696
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

To date, the pathogenesis of severe acute respiratory syndrome (SARS) in humans is still not well understood. SARS coronavirus (SARS-CoV)-specific CTL responses, in particular their magnitude and duration of postinfection immunity, have not been extensively studied. In this study, we found that heat-inactivated SARS-CoV elicited recall CTL responses to newly identified spike protein-derived epitopes (SSp-1, S978, and S1202) in peripheral blood of all HLA-A*0201(+) recovered SARS patients over 1 year postinfection. Intriguingly, heat-inactivated SARS-CoV elicited recall-like CTL responses to SSp-1 but not to S978, S1202, or dominant epitopes from several other human viruses in 5 of 36 (13.8%) HLA-A*0201(+) healthy donors without any contact history with SARS-CoV. SSp-1-specific CTLs expanded from memory T cells of both recovered SARS patients, and the five exceptional healthy donors shared a differentiated effector CTL phenotype, CD45RA(+)CCR7(-)CD62L(-), and expressed CCR5 and CD44. However, compared with the high avidity of SSp-1-specific CTLs derived from memory T cells of recovered SARS patients, SSp-1-specific CTLs from the five exceptional healthy donors were of low avidity, as determined by their rapid tetramer dissociation kinetics and reduced cytotoxic reactivity, IFN-gamma secretion, and intracellular production of IFN-gamma, TNF-alpha, perforin, and granzyme A. These results indicate that SARS-CoV infection induces strong and long-lasting CTL-mediated immunity in surviving SARS patients, and that cross-reactive memory T cells to SARS-CoV may exist in the T cell repertoire of a small subset of healthy individuals and can be reactivated by SARS-CoV infection.

Citing Articles

Neuro-PASC is characterized by enhanced CD4+ and diminished CD8+ T cell responses to SARS-CoV-2 Nucleocapsid protein.

Visvabharathy L, Hanson B, Orban Z, Lim P, Palacio N, Jimenez M Front Immunol. 2023; 14:1155770.

PMID: 37313412 PMC: 10258318. DOI: 10.3389/fimmu.2023.1155770.


Broadly recognized, cross-reactive SARS-CoV-2 CD4 T cell epitopes are highly conserved across human coronaviruses and presented by common HLA alleles.

Becerra-Artiles A, Calvo-Calle J, Co M, Nanaware P, Cruz J, Weaver G Cell Rep. 2022; 39(11):110952.

PMID: 35675811 PMC: 9135679. DOI: 10.1016/j.celrep.2022.110952.


Peculiarities of the T Cell Immune Response in COVID-19.

Kudlay D, Kofiadi I, Khaitov M Vaccines (Basel). 2022; 10(2).

PMID: 35214700 PMC: 8877307. DOI: 10.3390/vaccines10020242.


T cell responses to SARS-CoV-2 in humans and animals.

Mattoo S, Myoung J J Microbiol. 2022; 60(3):276-289.

PMID: 35157219 PMC: 8852923. DOI: 10.1007/s12275-022-1624-z.


Susceptibility to COVID-19 in Pregnancy, Labor, and Postpartum Period: Immune System, Vertical Transmission, and Breastfeeding.

Vale A, Fernandes A, Guzen F, Irochima Pinheiro F, de Azevedo E, Cobucci R Front Glob Womens Health. 2021; 2:602572.

PMID: 34816177 PMC: 8593969. DOI: 10.3389/fgwh.2021.602572.